GB2407500A - Use of microparticles for antigen delivery - Google Patents

Use of microparticles for antigen delivery Download PDF

Info

Publication number
GB2407500A
GB2407500A GB0325624A GB0325624A GB2407500A GB 2407500 A GB2407500 A GB 2407500A GB 0325624 A GB0325624 A GB 0325624A GB 0325624 A GB0325624 A GB 0325624A GB 2407500 A GB2407500 A GB 2407500A
Authority
GB
United Kingdom
Prior art keywords
pro
lys
tat
gln
cys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0325624A
Other languages
English (en)
Other versions
GB0325624D0 (en
Inventor
Barbara Ensoli
Antonella Caputo
Michelle Laus
Luisa Tondelli
Katia Sparnacci
Riccardo Gavioli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto Superiore di Sanità
Original Assignee
Istituto Superiore di Sanità
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Superiore di Sanità filed Critical Istituto Superiore di Sanità
Priority to GB0325624A priority Critical patent/GB2407500A/en
Publication of GB0325624D0 publication Critical patent/GB0325624D0/en
Priority to PCT/EP2004/012421 priority patent/WO2005049093A1/en
Priority to US10/577,974 priority patent/US20070275071A1/en
Priority to EP04797558A priority patent/EP1696964A1/en
Priority to JP2006537243A priority patent/JP2007509903A/ja
Publication of GB2407500A publication Critical patent/GB2407500A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
GB0325624A 2003-11-03 2003-11-03 Use of microparticles for antigen delivery Withdrawn GB2407500A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GB0325624A GB2407500A (en) 2003-11-03 2003-11-03 Use of microparticles for antigen delivery
PCT/EP2004/012421 WO2005049093A1 (en) 2003-11-03 2004-11-03 Use of microparticles for antigen delivery
US10/577,974 US20070275071A1 (en) 2003-11-03 2004-11-03 Use of Microparticles for Antigen Delivery
EP04797558A EP1696964A1 (en) 2003-11-03 2004-11-03 Use of microparticles for antigen delivery
JP2006537243A JP2007509903A (ja) 2003-11-03 2004-11-03 抗原送達のための微粒子の使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0325624A GB2407500A (en) 2003-11-03 2003-11-03 Use of microparticles for antigen delivery

Publications (2)

Publication Number Publication Date
GB0325624D0 GB0325624D0 (en) 2003-12-10
GB2407500A true GB2407500A (en) 2005-05-04

Family

ID=29725849

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0325624A Withdrawn GB2407500A (en) 2003-11-03 2003-11-03 Use of microparticles for antigen delivery

Country Status (5)

Country Link
US (1) US20070275071A1 (enExample)
EP (1) EP1696964A1 (enExample)
JP (1) JP2007509903A (enExample)
GB (1) GB2407500A (enExample)
WO (1) WO2005049093A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2496482C2 (ru) * 2008-03-05 2013-10-27 Бакстер Интернэшнл Инк. Композиции и способы для доставки лекарственных средств
US8323696B2 (en) * 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
JP5692933B2 (ja) 2009-03-23 2015-04-01 ナニアールエックス セラピューティックス インコーポレイテッド 免疫刺激ＨＩＶＴａｔ誘導体ポリペプチドによる腫瘍治療
EP2525815B1 (en) * 2010-01-24 2015-02-25 Novartis AG Irradiated biodegradable polymer microparticles
US9717827B2 (en) * 2012-09-12 2017-08-01 The Regents Of The University Of California Immunomodulatory materials for implantable medical devices
EP3107568B1 (en) * 2014-02-20 2024-03-27 Vaxart, Inc. Formulations for small intestinal delivery
AU2015236147A1 (en) * 2014-03-25 2016-10-13 Duke University Mosaic HIV-1 sequences and uses thereof
KR102678401B1 (ko) 2015-06-12 2024-06-26 박사르트, 인크. Rsv 및 노로바이러스 항원들의 소장 내의 전달을 위한 제형들
WO2019161171A1 (en) * 2018-02-16 2019-08-22 Sperovie Biosciences, Inc. Nanoparticle formulations of sting agonists
IL303390A (en) 2020-12-03 2023-08-01 Battelle Memorial Institute Compositions of polymer nanoparticles and DNA nanostructures and methods for non-viral transport
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
AU2024393766A1 (en) 2023-12-08 2026-06-18 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026376A2 (en) * 1994-03-28 1995-10-05 University Of Nottingham Polymer microspheres and a method of production thereof
WO2000012065A1 (en) * 1998-08-27 2000-03-09 West Pharmaceutical Services Microparticulate composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3048883A1 (de) * 1980-12-23 1982-07-15 Boehringer Mannheim Gmbh, 6800 Mannheim Hydrophile latexpartikel, verfahren zu deren herstellung und deren verwendung
EP0054685B1 (de) * 1980-12-23 1986-07-09 Roche Diagnostics GmbH Hydrophile Latexpartikel, Verfahren zu deren Herstellung und deren Verwendung
FR2596399B1 (fr) * 1986-03-28 1988-09-02 Univ Rennes Nanoparticules a base de polymere ou copolymere methacrylique, procede de preparation, et application comme vecteur de medicament
US5334394A (en) * 1990-06-22 1994-08-02 The Regents Of The University Of California Human immunodeficiency virus decoy
WO2002000191A2 (de) * 2000-06-29 2002-01-03 Bernina Biosystems Gmbh Bdellosomen
DE10118852A1 (de) * 2001-04-17 2002-10-31 Fricker Gert Bdellosomen
WO2002026212A2 (en) * 2000-09-28 2002-04-04 Chiron Corporation Microparticle compositions and methods for the manufacture thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026376A2 (en) * 1994-03-28 1995-10-05 University Of Nottingham Polymer microspheres and a method of production thereof
WO2000012065A1 (en) * 1998-08-27 2000-03-09 West Pharmaceutical Services Microparticulate composition

Also Published As

Publication number Publication date
GB0325624D0 (en) 2003-12-10
WO2005049093A1 (en) 2005-06-02
EP1696964A1 (en) 2006-09-06
JP2007509903A (ja) 2007-04-19
US20070275071A1 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
US20060280798A1 (en) Nanoparticles for delivery of a pharmacologically active agent
Li et al. P22 virus-like particles as an effective antigen delivery nanoplatform for cancer immunotherapy
Azuar et al. Poly (hydrophobic amino acid)-based self-adjuvanting nanoparticles for Group A Streptococcus vaccine delivery
CA2884677C (en) Cell penetrating peptides derived from the epstein barr virus, compositions and methods thereof
US9782475B2 (en) Method of treating food allergies by administering a nanoparticle comprising heparin and chitosan encapsulating IL-12
WO2002100325A2 (en) Polyvalent nanoparticles
Xu et al. A versatile supramolecular nanoadjuvant that activates NF-κB for cancer immunotherapy
Castaldello et al. DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination
US20070275071A1 (en) Use of Microparticles for Antigen Delivery
Avila et al. Gene delivery and immunomodulatory effects of plasmid DNA associated with Branched Amphiphilic Peptide Capsules
KR20140100417A (ko) 경피 투여용 백신 조성물
Voltan et al. Preparation and characterization of innovative protein-coated poly (methylmethacrylate) core-shell nanoparticles for vaccine purposes
EP4138876A1 (en) Immunization against sars-cov-related diseases
CA2759727A1 (en) Hydrogels for combinatorial delivery of immune-modulating biomolecules
Park et al. Multilayer adjuvanted influenza protein nanoparticles improve intranasal delivery and antigen-specific immunity
AU2003228229A1 (en) DNA vaccine against proliferating endothelial cells and methods of use thereof
Caputo et al. Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application
CN102131931A (zh) 递送腺病毒载体的衔接分子
EP1029549B1 (en) Formulation of nucleic acids and acemannan
US20220257753A1 (en) Vaccine Adjuvants for Antigen Delivery
CA2840335C (en) Recombinant mistletoe lectin and use thereof as an adjuvant
Szachniewicz et al. Adapted from Int J Pharm. 2024; 666: 124842
Chesson Supramolecular Peptide Nanofiber Vaccines for Eliciting CD8+ T-cell Responses
EP4601685A1 (en) Modified long peptides suitable for use in immunisation
Chiu Evaluation of Calcium Phosphate Nanoparticles Mineralized with Proteins and Peptides for Use as Adjuvants in Protein and Nucleic Acid Vaccines

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)